SCHEMBL2653523

SCHEMBL2653523

CC(OCc1ncc[nH]1)c1cccc(-n2cnc3cc(C=O)ccc32)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 10/20 0.43
HPGD P15428 3/20 0.39
SRC P12931 3/20 0.36
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GABRP O00591 2/20 0.34
GABRD O14764 2/20 0.34
GABRA1 P14867 2/20 0.34
GABRB1 P18505 2/20 0.34
GABRG2 P18507 2/20 0.34
GABRB3 P28472 2/20 0.34
GABRA5 P31644 2/20 0.34
GABRA3 P34903 2/20 0.34
GABRA2 P47869 2/20 0.34
GABRB2 P47870 2/20 0.34
GABRA4 P48169 2/20 0.34
GABRE P78334 2/20 0.34
GABRA6 Q16445 2/20 0.34
GABRG1 Q8N1C3 2/20 0.34
GABRG3 Q99928 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2652698 0.90 HPGD (0.38) FGFR1HPGDSRCMAPK1SMN1; SMN2
SCHEMBL2653928 0.85 GABRP (0.40) FGFR1HPGDSRCMAPK1SMN1; SMN2
SCHEMBL2974099 0.85 HPGD (0.39) FGFR1HPGDSRCMAPK1SMN1; SMN2
SCHEMBL2977952 0.85 HPGD (0.37) FGFR1HPGDSRCMAPK1SMN1; SMN2
SCHEMBL2966390 0.83 FGFR1 (0.44) FGFR1HPGDSRCMAPK1SMN1; SMN2
SCHEMBL2652428 0.82 HPGD (0.45) FGFR1HPGDMAPK1SMN1; SMN2GABRA1
SCHEMBL2978344 0.81 HPGD (0.39) FGFR1HPGDMAPK1SMN1; SMN2
SCHEMBL2652210 0.81 HPGD (0.42) FGFR1HPGDSRCSMN1; SMN2GABRP
SCHEMBL2652696 0.73 FGFR1 (0.36) FGFR1HPGDSRCMAPK1SMN1; SMN2
SCHEMBL28722636 0.70 FGFR1 (0.63) FGFR1HPGDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1874758-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2008-01-09 EP claimed
WO-2006111516-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2006-10-26 WO claimed
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US disclosed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex GABRB2, GABRB1, GABRB3 FGFR1 4324/4885HPGD 1855/4885SRC 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.